Markers of intestinal inflammation in patients with ankylosing spondylitis: A pilot study

Arthritis Research and Therapy

Volumn 14, Issue 6, 2012, Pages

  Matzkies, Franziska G ^a   Targan, Stephan R ^b   Berel, Dror ^b   Landers, Carol J ^b   Reveille, John D ^c   McGovern, Dermot P B ^b   Weisman, Michael H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN; FLAGELLIN; HLA B27 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; MALE; PILOT STUDY; SEROLOGY; AGED; BLOOD; CHEMISTRY; COHORT ANALYSIS; FECES; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PILOT PROJECTS; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

EID: 84870062198     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4106     Document Type: Article

References (43)

1. Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep 2011, 13:409-415. 10.1007/s11926-011-0198-2, 21744132.
2. Rosenbaum J, Chandran V. Management of comorbidities in ankylosing spondylitis. Am J Med Sci 2012, 343:364-366. 10.1097/MAJ.0b013e3182514059, 22543539.
3. De Keyser F, Elewaut D, De Vos M, De Vlam K, Cuvelier C, Mielants H, Veys EM. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 1998, 24:785-813. ix-x, 10.1016/S0889-857X(05)70042-9, 9891711.
4. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppala K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994, 37:23-31. 10.1002/art.1780370105, 8129761.
5. Mielants H, Veys EM, Cuvelier C, de Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol 1988, 27(Suppl 2):95-105.
6. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995, 22:2273-2278.
7. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Gyselbrecht L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995, 22:2279-2284.
8. Mielants H, Bosch F. Inflammatory bowel disease spondyloarthritis: epidemiology, clinical features, and treatment. Ankylosing Spondylitis and the Spondlyoarthropathies 2006, Philadelphia, PA: Mosby, Weisman MH, Reveille JD, van der Heijde D, 1.
9. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Gatta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, , Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, et al. NIDDK IBD Genetics Consortium Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962. 10.1038/ng.175, 2574810, 18587394, NIDDK IBD Genetics Consortium.
10. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Matthew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010, 42:1118-1125. 10.1038/ng.717, 3299551, 21102463.
11. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Legacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011, 43:246-252. 10.1038/ng.764, 3084597, 21297633.
12. Franke A, Balschun T, Sina C, Ellinghaus D, Häsler R, Mayr G, Albrecht M, Wittig M, Buchert E, Nikolaus S, Gieger C, Wichmann HE, Sventoraityte J, Kupcinskas L, Onnie CM, Gazouli M, Anagnou NP, Strachan D, McArdle WL, Mathew CG, Rutgeerts P, Vermeire S, Vatn MH, , Krawczak M, Rosenstiel P, Karlsen TH, Schreiber S. IBSEN Study Group Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat Genet 2010, 42:292-294. 10.1038/ng.553, 20228798, IBSEN Study Group.
13. Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005, 14:3499-3506. 10.1093/hmg/ddi379, 16221758.
14. Thjodleifsson B, Geirsson AJ, Bjornsson S, Bjarnason I. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum 2007, 56:2633-2639. 10.1002/art.22812, 17665420.
15. Taurog JD. The role of HLA-B27 in spondyloarthritis. J Rheumatol 2010, 37:2606-2616. 10.3899/jrheum.100889, 21123333.
16. Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009, 15:2449-2455. 10.3748/wjg.15.2449, 2686901, 19468993.
17. Jacques P, Elewaut D, Mielants H. Interactions between gut inflammation and arthritis/spondylitis. Curr Opin Rheumatol 2010, 22:368-374. 10.1097/BOR.0b013e3283393807, 20485176.
18. Danoy P, Pryce K, Hadler J, Bradbury LA, Farrar C, Pointon J, , Ward M, Weisman M, Reveille JD, Wordsworth BP, Stone MA, , Maksymowych WP, Rahman P, Gladman D, Inman RD, Brown MA. Australo-Anglo-American Spondyloarthritis Consortium, Spondyloarthritis Research Consortium of Canada Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet 2010, 6:e1001195. 10.1371/journal.pgen.1001195, 2996314, 21152001, Australo-Anglo-American Spondyloarthritis Consortium, Spondyloarthritis Research Consortium of Canada.
19. Martinez-Gonzalez O, Cantero-Hinojosa J, Paule-Sastre P, Gomez-Magan JC, Salvatierra-Rios D. Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives. Br J Rheumatol 1994, 33:644-647. 10.1093/rheumatology/33.7.644, 8019793.
20. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998, 42:788-791. 10.1136/gut.42.6.788, 1727156, 9691915.
21. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005, 128:2020-2028. 10.1053/j.gastro.2005.03.046, 15940634.
22. Mundwiler ML, Mei L, Landers CJ, Reveille JD, Targan S, Weisman MH. Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study. Arthritis Res Ther 2009, 11:R177. 10.1186/ar2866, 3003540, 19930665.
23. Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 2008, 47:142-144.
24. Torok HP, Glas J, Gruber R, Brumberger V, Strasser C, Kellner H, Marker-Hermann E, Folwaczny C. Inflammatory bowel disease-specific autoantibodies in HLA-B27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA. Digestion 2004, 70:49-54. 10.1159/000080081, 15308872.
25. Riente L, Chimenti D, Pratesi F, Delle Sedie A, Tommasi S, Tommasi C, Bombardieri S, Migliorini P. Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol 2004, 31:920-924.
26. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflammatory Bowel Dis 2006, 12:524-534.
27. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000, 47:506-513. 10.1136/gut.47.4.506, 1728060, 10986210.
28. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001, 32:171-177. 10.1097/00005176-200102000-00015, 11321388.
29. Lee W, Reveille JD, Davis JC, Learch TJ, Ward MM, Weisman MH. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis 2007, 66:633-638. 10.1136/ard.2006.060293, 1954622, 17127685.
30. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368. 10.1002/art.1780270401, 6231933.
31. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002, 123:689-699. 10.1053/gast.2002.35379, 12198693.
32. Papadakis KA, Yang H, Ippoliti A, Mei L, Elson CO, Hershberg RM, Vasiliauskas EA, Fleshner PR, Abreu MT, Taylor K, Landers CJ, Rotter JI, Targan SR. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflammatory Bowel Dis 2007, 13:524-530.
33. Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-d'Elia H. Calprotectin in ankylosing spondylitis - frequently elevated in feces, but normal in serum. Scand J Gastroenterol 2012, 47:435-444. 10.3109/00365521.2011.648953, 22229862.
34. Stoll ML, Punaro M, Patel AS. Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis. J Rheumatol 2011, 38:2274-2275. 10.3899/jrheum.110508, 21965700.
35. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006, 20:451-471. 10.1016/j.berh.2006.03.010, 16777576.
36. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035. 10.1056/NEJM199710093371502, 9321530.
37. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405. 10.1056/NEJM199905063401804, 10228190.
38. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999, 116:22-28. 10.1016/S0016-5085(99)70224-6, 9869598.
39. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Licentenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. A randomized placebo-controlled trial of infliximab for active ulcerative colitis: the ACT I trial. Gastroenterology 2005, 128(Suppl 2):A105.
40. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003, 62:74-76. 10.1136/ard.62.1.74, 1754306, 12480676.
41. Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, Tokioka S, Arakawa T. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009, 44:879-888. 10.1007/s00535-009-0102-2, 19568687.
42. von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, Paraskeva P, Tekkis PP. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007, 102:803-813. 10.1111/j.1572-0241.2007.01126.x, 17324124.
43. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S, Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, Weisman MH, Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowych W, Gladman D, Rahman P, , Morgan A, Marzo-Ortega H, Bowness P, et al. Spondyloarthritis Research Consortium of Canada Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011, 43:761-767. 10.1038/ng.873, 21743469, Spondyloarthritis Research Consortium of Canada.